Sensei Biotherapeutics reports Q1 2023 net loss of $10.2M; IND cleared for SNS-101 Phase 1/2 trial

Sensei Biotherapeutics, Inc.

2023-Q1 EPS reported -$0.33

Cash, cash equivalents and marketable securities were $95.5M as of March 31, 2023; cash runway into H2 2025.
Net loss was $10.2M for Q1 2023, compared to $12.4M for Q1 2022; R&D expenses decreased to $5.2M.
FDA cleared IND for SNS-101 (conditionally active anti-VISTA antibody); Phase 1/2 trial enrollment and dosing expected mid-2023.
CRADA signed with NCI for VISTA research; SNS-102 and SNS-103 candidate selection on track for 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $10.2 million.

Period: the first quarter ended March 31, 2023
Net income: $10.2 million
Result: reported results

Exact text from the filing

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2023, and provided recent business updates.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-138934

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.